Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis

Relationship with suppression of circulating TGF-Β1

S. G. Kim, Y. M. Kim, Y. H. Choi, M. G. Lee, J. Y. Choi, J. Y. Han, S. H. Cho, J. W. Jang, Soon-Ho Um, C. Y. Chon, D. H. Lee, J. J. Jang, E. S. Yu, Y. S. Lee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Oltipraz is a potential candidate drug for the treatment of liver fibrosis (LF) and liver cirrhosis (LC). The pharmacokinetics of oltipraz and its major rearranged metabolite (7-methyl-6,8-bis(methylthio)H-pyrrolo1,2-apyrazine (RM)) were evaluated after single-dose (3090mg) and multiple-dose (60mg b.i.d. or 90mg q.d. for 24 weeks) oral administration of oltipraz to patients with LF or LC. Oltipraz was safe and well tolerated in both studies. In the single-dose study, the area under the plasma concentration-time curve (AUC), peak plasma concentration (Cmax), and terminal half-life (t 1/2) of oltipraz as well as the AUC of its RM were dose dependent. Oltipraz was rapidly absorbed; the time to reach Cmax (Tma) was 2-4h. The conversion of oltipraz to RM was also rapid and substantial (AUC of RM from time 0 to the last measured concentration (AUClast, RM)/AUClast, oltipraz, 4261%). In the multiple-dose study, the level of transforming growth factor-Β1 (TGF-Β1) (a blood fibrosis marker) was suppressed at steady-state plasma concentrations of ∼2060ng/ml of oltipraz or of ∼60140ng/ml of oltipraz plus RM. Overall, the pharmacokinetics, safety, and efficacy of oltipraz suggest that it may be helpful in the treatment of patients with LF or LC, at an optimal dosing regimen.

Original languageEnglish
Pages (from-to)360-368
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume88
Issue number3
DOIs
Publication statusPublished - 2010 Sep 1

Fingerprint

Transforming Growth Factors
Liver Cirrhosis
Pharmacokinetics
Area Under Curve
oltipraz
Oral Administration
Half-Life
Fibrosis
Safety

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis : Relationship with suppression of circulating TGF-Β1. / Kim, S. G.; Kim, Y. M.; Choi, Y. H.; Lee, M. G.; Choi, J. Y.; Han, J. Y.; Cho, S. H.; Jang, J. W.; Um, Soon-Ho; Chon, C. Y.; Lee, D. H.; Jang, J. J.; Yu, E. S.; Lee, Y. S.

In: Clinical Pharmacology and Therapeutics, Vol. 88, No. 3, 01.09.2010, p. 360-368.

Research output: Contribution to journalArticle

Kim, SG, Kim, YM, Choi, YH, Lee, MG, Choi, JY, Han, JY, Cho, SH, Jang, JW, Um, S-H, Chon, CY, Lee, DH, Jang, JJ, Yu, ES & Lee, YS 2010, 'Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: Relationship with suppression of circulating TGF-Β1', Clinical Pharmacology and Therapeutics, vol. 88, no. 3, pp. 360-368. https://doi.org/10.1038/clpt.2010.89
Kim, S. G. ; Kim, Y. M. ; Choi, Y. H. ; Lee, M. G. ; Choi, J. Y. ; Han, J. Y. ; Cho, S. H. ; Jang, J. W. ; Um, Soon-Ho ; Chon, C. Y. ; Lee, D. H. ; Jang, J. J. ; Yu, E. S. ; Lee, Y. S. / Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis : Relationship with suppression of circulating TGF-Β1. In: Clinical Pharmacology and Therapeutics. 2010 ; Vol. 88, No. 3. pp. 360-368.
@article{58942bfc3fd6437baaaf2979d6e7ba2e,
title = "Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: Relationship with suppression of circulating TGF-Β1",
abstract = "Oltipraz is a potential candidate drug for the treatment of liver fibrosis (LF) and liver cirrhosis (LC). The pharmacokinetics of oltipraz and its major rearranged metabolite (7-methyl-6,8-bis(methylthio)H-pyrrolo1,2-apyrazine (RM)) were evaluated after single-dose (3090mg) and multiple-dose (60mg b.i.d. or 90mg q.d. for 24 weeks) oral administration of oltipraz to patients with LF or LC. Oltipraz was safe and well tolerated in both studies. In the single-dose study, the area under the plasma concentration-time curve (AUC), peak plasma concentration (Cmax), and terminal half-life (t 1/2) of oltipraz as well as the AUC of its RM were dose dependent. Oltipraz was rapidly absorbed; the time to reach Cmax (Tma) was 2-4h. The conversion of oltipraz to RM was also rapid and substantial (AUC of RM from time 0 to the last measured concentration (AUClast, RM)/AUClast, oltipraz, 4261{\%}). In the multiple-dose study, the level of transforming growth factor-Β1 (TGF-Β1) (a blood fibrosis marker) was suppressed at steady-state plasma concentrations of ∼2060ng/ml of oltipraz or of ∼60140ng/ml of oltipraz plus RM. Overall, the pharmacokinetics, safety, and efficacy of oltipraz suggest that it may be helpful in the treatment of patients with LF or LC, at an optimal dosing regimen.",
author = "Kim, {S. G.} and Kim, {Y. M.} and Choi, {Y. H.} and Lee, {M. G.} and Choi, {J. Y.} and Han, {J. Y.} and Cho, {S. H.} and Jang, {J. W.} and Soon-Ho Um and Chon, {C. Y.} and Lee, {D. H.} and Jang, {J. J.} and Yu, {E. S.} and Lee, {Y. S.}",
year = "2010",
month = "9",
day = "1",
doi = "10.1038/clpt.2010.89",
language = "English",
volume = "88",
pages = "360--368",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis

T2 - Relationship with suppression of circulating TGF-Β1

AU - Kim, S. G.

AU - Kim, Y. M.

AU - Choi, Y. H.

AU - Lee, M. G.

AU - Choi, J. Y.

AU - Han, J. Y.

AU - Cho, S. H.

AU - Jang, J. W.

AU - Um, Soon-Ho

AU - Chon, C. Y.

AU - Lee, D. H.

AU - Jang, J. J.

AU - Yu, E. S.

AU - Lee, Y. S.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Oltipraz is a potential candidate drug for the treatment of liver fibrosis (LF) and liver cirrhosis (LC). The pharmacokinetics of oltipraz and its major rearranged metabolite (7-methyl-6,8-bis(methylthio)H-pyrrolo1,2-apyrazine (RM)) were evaluated after single-dose (3090mg) and multiple-dose (60mg b.i.d. or 90mg q.d. for 24 weeks) oral administration of oltipraz to patients with LF or LC. Oltipraz was safe and well tolerated in both studies. In the single-dose study, the area under the plasma concentration-time curve (AUC), peak plasma concentration (Cmax), and terminal half-life (t 1/2) of oltipraz as well as the AUC of its RM were dose dependent. Oltipraz was rapidly absorbed; the time to reach Cmax (Tma) was 2-4h. The conversion of oltipraz to RM was also rapid and substantial (AUC of RM from time 0 to the last measured concentration (AUClast, RM)/AUClast, oltipraz, 4261%). In the multiple-dose study, the level of transforming growth factor-Β1 (TGF-Β1) (a blood fibrosis marker) was suppressed at steady-state plasma concentrations of ∼2060ng/ml of oltipraz or of ∼60140ng/ml of oltipraz plus RM. Overall, the pharmacokinetics, safety, and efficacy of oltipraz suggest that it may be helpful in the treatment of patients with LF or LC, at an optimal dosing regimen.

AB - Oltipraz is a potential candidate drug for the treatment of liver fibrosis (LF) and liver cirrhosis (LC). The pharmacokinetics of oltipraz and its major rearranged metabolite (7-methyl-6,8-bis(methylthio)H-pyrrolo1,2-apyrazine (RM)) were evaluated after single-dose (3090mg) and multiple-dose (60mg b.i.d. or 90mg q.d. for 24 weeks) oral administration of oltipraz to patients with LF or LC. Oltipraz was safe and well tolerated in both studies. In the single-dose study, the area under the plasma concentration-time curve (AUC), peak plasma concentration (Cmax), and terminal half-life (t 1/2) of oltipraz as well as the AUC of its RM were dose dependent. Oltipraz was rapidly absorbed; the time to reach Cmax (Tma) was 2-4h. The conversion of oltipraz to RM was also rapid and substantial (AUC of RM from time 0 to the last measured concentration (AUClast, RM)/AUClast, oltipraz, 4261%). In the multiple-dose study, the level of transforming growth factor-Β1 (TGF-Β1) (a blood fibrosis marker) was suppressed at steady-state plasma concentrations of ∼2060ng/ml of oltipraz or of ∼60140ng/ml of oltipraz plus RM. Overall, the pharmacokinetics, safety, and efficacy of oltipraz suggest that it may be helpful in the treatment of patients with LF or LC, at an optimal dosing regimen.

UR - http://www.scopus.com/inward/record.url?scp=77955920049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955920049&partnerID=8YFLogxK

U2 - 10.1038/clpt.2010.89

DO - 10.1038/clpt.2010.89

M3 - Article

VL - 88

SP - 360

EP - 368

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -